Jagsonpal Pharmaceuticals Crecimiento futuro

Future controles de criterios 0/6

Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de Jagsonpal Pharmaceuticals.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	17.0%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	None
Última actualización	n/a

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

There May Be Some Bright Spots In Jagsonpal Pharmaceuticals' (NSE:JAGSNPHARM) Earnings

May 27

There's Reason For Concern Over Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) Massive 27% Price Jump

Apr 30

A Look At The Fair Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Apr 05

Investor Optimism Abounds Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) But Growth Is Lacking

Feb 06

Estimating The Intrinsic Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Jul 29

A Look At The Intrinsic Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

May 13

Does Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) Deserve A Spot On Your Watchlist?

Jul 05

A Look At The Fair Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Jun 13

Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) 0.6% Dividend Yield Looks Pretty Interesting

Apr 19

Should You Be Adding Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) To Your Watchlist Today?

Mar 21

Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) Stock Is Going Strong: Have Financials A Role To Play?

Feb 08

The Attractive Combination That Could Earn Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) A Place In Your Dividend Portfolio

Jan 08

Here's Why I Think Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) Is An Interesting Stock

Dec 21

Are Jagsonpal Pharmaceuticals's (NSE:JAGSNPHARM) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Nov 30

En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como Jagsonpal Pharmaceuticals no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.

Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.

Previsiones de crecimiento de beneficios e ingresos

NSEI:JAGSNPHARM - Estimaciones futuras de los analistas y datos financieros pasados (INR Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
3/31/2024	2,087	225	349	352	N/A
12/31/2023	2,207	245	N/A	N/A	N/A
9/30/2023	2,336	283	492	498	N/A
6/30/2023	2,363	313	N/A	N/A	N/A
3/31/2023	2,367	267	463	467	N/A
12/31/2022	2,410	223	N/A	N/A	N/A
9/30/2022	2,348	198	-2	-1	N/A
6/30/2022	2,326	131	N/A	N/A	N/A
3/31/2022	2,176	189	59	69	N/A
12/31/2021	2,168	247	N/A	N/A	N/A
9/30/2021	2,194	247	308	316	N/A
6/30/2021	2,163	214	N/A	N/A	N/A
3/31/2021	1,879	171	278	282	N/A
12/31/2020	1,746	135	N/A	N/A	N/A
9/30/2020	1,595	104	200	210	N/A
6/30/2020	1,450	84	N/A	N/A	N/A
3/31/2020	1,586	79	100	119	N/A
12/31/2019	1,675	93	N/A	N/A	N/A
9/30/2019	1,673	88	N/A	N/A	N/A
6/30/2019	1,697	85	N/A	N/A	N/A
3/31/2019	1,668	72	286	309	N/A
12/31/2018	1,611	30	N/A	N/A	N/A
9/30/2018	1,573	-10	N/A	N/A	N/A
6/30/2018	1,421	-66	N/A	N/A	N/A
3/31/2018	1,266	-116	-54	-16	N/A
12/31/2017	1,234	-95	N/A	N/A	N/A
9/30/2017	1,193	26	N/A	N/A	N/A
6/30/2017	1,305	70	N/A	N/A	N/A
4/1/2017	1,441	119	N/A	-32	N/A
12/31/2016	1,534	131	N/A	N/A	N/A
9/30/2016	1,537	35	N/A	N/A	N/A
6/30/2016	1,466	34	N/A	N/A	N/A
3/31/2016	1,435	33	N/A	90	N/A
12/31/2015	1,434	13	N/A	N/A	N/A
9/30/2015	1,412	10	N/A	N/A	N/A
6/30/2015	1,412	9	N/A	N/A	N/A
3/31/2015	1,382	12	N/A	43	N/A
12/31/2014	1,306	23	N/A	N/A	N/A
9/30/2014	1,359	32	N/A	N/A	N/A
6/30/2014	1,397	28	N/A	N/A	N/A
3/31/2014	1,439	21	N/A	75	N/A
12/31/2013	1,507	12	N/A	N/A	N/A
9/30/2013	1,623	14	N/A	N/A	N/A
6/30/2013	1,673	18	N/A	N/A	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de JAGSNPHARM es superior a la tasa de ahorro (6.7%).

Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de JAGSNPHARM crezcan más rápidamente que el mercado Indian

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de JAGSNPHARM crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de JAGSNPHARM crezcan más rápidamente que el mercado de Indian.

Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de JAGSNPHARM crezcan a un ritmo superior a 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de JAGSNPHARM se prevé que sea elevada dentro de 3 años.

Jagsonpal Pharmaceuticals Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

New minor risk - Market cap size

There May Be Some Bright Spots In Jagsonpal Pharmaceuticals' (NSE:JAGSNPHARM) Earnings

Full year 2024 earnings released: EPS: ₹8.49 (vs ₹10.20 in FY 2023)

There's Reason For Concern Over Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) Massive 27% Price Jump

Investor sentiment improves as stock rises 16%

A Look At The Fair Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Now 20% undervalued after recent price drop

Investor Optimism Abounds Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) But Growth Is Lacking

New minor risk - Market cap size

Third quarter 2024 earnings released: EPS: ₹1.48 (vs ₹2.97 in 3Q 2023)

Jagsonpal Pharmaceuticals Limited Announces Chief Financial Officer Changes

Jagsonpal Pharmaceuticals Limited to Report Q3, 2023 Results on Feb 01, 2024

Now 20% undervalued after recent price drop

Now 23% undervalued after recent price drop

Now 20% undervalued after recent price drop

Second quarter 2024 earnings released: EPS: ₹2.84 (vs ₹3.97 in 2Q 2023)

Jagsonpal Pharmaceuticals Limited to Report Q2, 2024 Results on Nov 03, 2023

Upcoming dividend of ₹5.00 per share at 1.1% yield

Jagsonpal Pharmaceuticals Limited, Annual General Meeting, Aug 31, 2023

First quarter 2024 earnings released: EPS: ₹2.85 (vs ₹0.14 in 1Q 2023)

Estimating The Intrinsic Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Jagsonpal Pharmaceuticals Limited to Report Q1, 2024 Results on Aug 02, 2023

Full year 2023 earnings released: EPS: ₹10.20 (vs ₹7.48 in FY 2022)

Jagsonpal Pharmaceuticals Limited Recommends Dividend for the Financial Year Ended March 31, 2023

Investor sentiment improves as stock rises 15%

Jagsonpal Pharmaceuticals Limited Announces Appointment of Abhishek Joshi as Company Secretary and Compliance Officer

Third quarter 2023 earnings released: EPS: ₹2.97 (vs ₹2.06 in 3Q 2022)

Jagsonpal Pharmaceuticals Limited Announces Executive Changes

Investor sentiment improved over the past week

High number of new and inexperienced directors

Second quarter 2023 earnings released: EPS: ₹3.97 (vs ₹2.79 in 2Q 2022)

High number of new and inexperienced directors

Jagsonpal Pharmaceuticals Limited, Annual General Meeting, Sep 14, 2022

First quarter 2023 earnings released: EPS: ₹0.14 (vs ₹2.61 in 1Q 2022)

Jagsonpal Pharmaceuticals Limited to Report Q1, 2023 Results on Aug 09, 2022

High number of new and inexperienced directors

Full year 2022 earnings released: EPS: ₹748 (vs ₹6.51 in FY 2021)

Jagsonpal Pharmaceuticals Limited to Report Q4, 2022 Results on May 30, 2022

Investor sentiment improved over the past week

A Look At The Intrinsic Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Jagsonpal Pharmaceuticals Limited Announces Resignation of Sanjiv Kumar Dudeja as Chief Financial Officer

Investor sentiment improved over the past week

Upcoming dividend of ₹4.00 per share

Second quarter 2022 earnings released: EPS ₹2.79 (vs ₹1.53 in 2Q 2021)

Upcoming dividend of ₹1.00 per share

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

First quarter 2022 earnings released: EPS ₹2.61 (vs ₹0.96 in 1Q 2021)

Investor sentiment improved over the past week

Does Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) Deserve A Spot On Your Watchlist?

Full year 2021 earnings released: EPS ₹6.51 (vs ₹3.00 in FY 2020)

Investor sentiment improved over the past week

A Look At The Fair Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) 0.6% Dividend Yield Looks Pretty Interesting

Should You Be Adding Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) To Your Watchlist Today?

New 90-day high: ₹93.35

Investor sentiment improved over the past week

Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) Stock Is Going Strong: Have Financials A Role To Play?

Jagsonpal Pharmaceuticals Limited to Report Q3, 2021 Results on Feb 12, 2021

The Attractive Combination That Could Earn Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) A Place In Your Dividend Portfolio

Insider recently bought ₹1.3m worth of stock

Investor sentiment improved over the past week

New 90-day high: ₹80.55

Insider recently bought ₹393k worth of stock

Here's Why I Think Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) Is An Interesting Stock

Insider recently bought ₹224k worth of stock

Insider recently bought ₹1.0m worth of stock

New 90-day high: ₹72.20

Market bids up stock over the past week